brozu ▪️A Phase 1 clinical trial on personalized #CancerVaccines for renal carcinoma reports promising results.
After 40 months, none of the 9 patients showed detectable recurrence. The approach involves sequencing tumor samples post-surgery to develop patient-specific vaccines, training the immune system to recognize and eliminate cancer cells.
Further studies are required, but these findings suggest potential clinical applications.
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma - Nature
A phase I trial of a neoantigen-targeting personalized cancer vaccine led to durable and polyfunctional T cell responses and antitumour recognition, and was associated with no recurrence in patients with high-risk clear cell renal cell carcinoma.
Victoria Stuart 🇨🇦 🏳️⚧️
The-14